What Makes Appeals Succeed: Lessons from the Data
The majority of denied claims are never appealed. According to KFF, fewer than 1 in 500 denied claims in Marketplace plans result in an appeal. Among the denials that are appealed, a significant percentage are overturned — data that suggests many practices are leaving recoverable revenue on the table simply by not engaging the appeals process.
But not all appeals are created equal. Some succeed and some fail, and the factors that separate winning appeals from losing ones are more predictable than most practice leaders realize. Research from payer transparency data, specialty society publications, and industry analyses points to several consistent success factors.
Factor One: Specificity of Clinical Evidence
The single most predictive factor in appeal success is whether the appeal cites patient-specific clinical evidence rather than generic medical necessity arguments. An appeal that states "this treatment is medically necessary" without supporting detail is fundamentally weaker than one that states "this patient's HbA1c of 9.2 despite 12 months of metformin monotherapy, combined with documented peripheral neuropathy progression, meets the clinical threshold for the requested therapy per the American Diabetes Association's Standards of Care."
The difference is not stylistic — it is structural. Payer reviewers, whether clinical staff or algorithm- assisted, evaluate appeals against specific coverage criteria. Appeals that map clinical evidence directly to those criteria force a substantive review. Generic appeals can be dismissed with a form letter.
A study published in Health Affairs examining Medicare Advantage appeals found that appeals containing specific clinical data points were significantly more likely to be overturned than those relying on general statements of necessity. The implication is clear: the time invested in gathering and organizing patient-specific clinical evidence pays dividends in appeal outcomes.
Factor Two: Guideline Citations
Appeals that cite published clinical practice guidelines outperform those that do not. This finding is consistent across multiple studies and across payer types. When a practice can demonstrate that the denied treatment aligns with guidelines from the relevant specialty society — whether the National Comprehensive Cancer Network (NCCN), the American College of Rheumatology, the American Heart Association, or others — the appeal carries substantially more weight.
The reason is partly legal and partly practical. Payers are increasingly scrutinized by regulators and courts for denying treatments that align with accepted clinical guidelines. An appeal that cites a guideline forces the payer to either accept the treatment or articulate why it is departing from established clinical standards — a position most payers prefer to avoid.
Importantly, the guideline citation must be specific. Referencing the general existence of a guideline is less effective than citing the specific recommendation, including the version, section, and recommendation strength. The more precisely the appeal connects the patient's clinical situation to a specific guideline recommendation, the stronger the case.
Factor Three: Timeliness
Appeals filed within the first 48 to 72 hours of denial notification consistently outperform those filed closer to the deadline. This correlation likely reflects multiple factors: practices that respond quickly tend to have more organized denial management processes, the clinical details are fresher, and the patient's treatment timeline may create urgency that influences the payer's review.
Timeliness also matters because many payers operate on a first-in, first-out basis for appeal reviews. An appeal filed at day two may be reviewed weeks before one filed at day 25, even though both are within the filing window. For patients awaiting treatment authorization, this difference in processing time can be clinically meaningful.
Factor Four: Understanding the Payer's Stated Reason
A surprising number of appeals fail because they address the wrong issue. When a payer denies a claim for "missing information" and the practice responds with a detailed clinical argument for medical necessity, the appeal misses the mark entirely. The payer did not question whether the treatment was necessary — it said it did not receive the information it needed to make that determination.
Successful appeals begin with a careful reading of the denial reason and respond to the specific deficiency cited. This sounds obvious, but in practice, many offices use standardized appeal templates that are not customized to the denial reason. A template that works well for a medical necessity denial may be entirely inappropriate for an eligibility denial or a timely filing denial.
Factor Five: Peer-to-Peer Review Execution
For denials that involve medical necessity determinations, requesting a peer-to-peer review with the payer's medical director is a high-value tactic — but only when executed well. The AMA has found that peer-to-peer reviews result in overturn rates significantly higher than written appeals alone, likely because the direct physician-to-physician conversation allows for nuance that written communication cannot convey.
However, peer-to-peer reviews that are poorly prepared can backfire. Physicians who enter the call without the patient's specific clinical data readily available, or who become adversarial rather than collegial, may actually reinforce the payer's denial decision. The most effective peer-to-peer calls are structured around three elements: the patient's specific clinical presentation, the clinical guideline that supports the requested treatment, and a clear explanation of why alternative treatments are clinically inappropriate for this specific patient.
Factor Six: Documentation of Prior Treatment Failure
For denials related to step therapy requirements, the quality of prior treatment failure documentation is decisive. Simply stating that a patient "failed" a previous therapy is insufficient. Successful appeals document the specific therapy tried, the dose and duration, the objective clinical response (or lack thereof), the reason for discontinuation, and any adverse effects experienced.
The Institute for Clinical and Economic Review (ICER) has published frameworks for evaluating treatment failure that can guide how practices document prior therapy. When the documentation shows a clear, objective treatment failure with measurable outcomes, the appeal for the next-line therapy becomes substantially stronger.
The Meta-Factor: Systematic Process
Underlying all of these individual factors is a meta-factor: whether the practice has a systematic appeal process or handles appeals ad hoc. Practices with defined workflows — including triage criteria, template libraries organized by payer and denial reason, clinical evidence checklists, and tracking systems — achieve higher overall appeal success rates than practices where appeals depend on the initiative and skill of individual staff members.
The research consistently shows that appeal success is not random. It is the product of specific, identifiable practices that can be learned, systematized, and improved over time. The practices that treat appeals as a data-driven discipline rather than an administrative chore are the ones that recover the most revenue — and the ones whose patients experience the fewest treatment disruptions.
The data does not lie: appeals work when they are done well. The challenge for most practices is building the infrastructure to do them well consistently, at scale, across every payer and every denial reason.